Abstract | PURPOSE: The availability of newly approved treatment options for metastatic castration resistant prostate cancer is not matched with conclusive data on optimal sequencing strategies and resistance patterns. A comprehensive review of efficacy and safety data for new agents and current knowledge regarding treatment sequencing would enable treating physicians to make rational drug selections in patients with metastatic castration resistant prostate cancer. MATERIALS AND METHODS: RESULTS: CONCLUSIONS: New therapies for metastatic castration resistant prostate cancer have brought new challenges with regard to treatment selection and sequencing. While hormonal agents provide good therapeutic responses, resistance may be intrinsic without prior drug exposure. Identifying predictors of response and relevant biomarkers will allow therapies to be more precisely tailored to individual patient profiles.
|
Authors | E David Crawford, Celestia S Higano, Neal D Shore, Maha Hussain, Daniel P Petrylak |
Journal | The Journal of urology
(J Urol)
Vol. 194
Issue 6
Pg. 1537-47
(Dec 2015)
ISSN: 1527-3792 [Electronic] United States |
PMID | 26196735
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Androgen Antagonists
- Androstenes
- Antineoplastic Agents
- Benzamides
- Nitriles
- Radioisotopes
- Taxoids
- Tissue Extracts
- Docetaxel
- Phenylthiohydantoin
- cabazitaxel
- sipuleucel-T
- enzalutamide
- abiraterone
- radium Ra 223 dichloride
- Radium
|
Topics |
- Androgen Antagonists
(adverse effects, therapeutic use)
- Androstenes
(adverse effects, therapeutic use)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Benzamides
- Disease Progression
- Docetaxel
- Humans
- Male
- Neoplasm Metastasis
(drug therapy, pathology)
- Neoplasm Staging
- Nitriles
- Orchiectomy
- Phenylthiohydantoin
(adverse effects, analogs & derivatives, therapeutic use)
- Prostatic Neoplasms, Castration-Resistant
(mortality, pathology, therapy)
- Radioisotopes
(adverse effects, therapeutic use)
- Radium
(adverse effects, therapeutic use)
- Survival Rate
- Taxoids
(administration & dosage, adverse effects, therapeutic use)
- Tissue Extracts
(adverse effects, therapeutic use)
|